Newsletter February 2022

PerkinElmer Life Science Reagents: The Keys to Expedite Drug Discovery (Webinar) Join us Wednesday, February 23rd at noon to learn how PerkinElmer is continuously developing meaningful solutions to help you advance your research and improve the drug development process.

During this webinar we will highlight our

• flagship detection assays
• newest targets
• and discuss how researchers in oncology, immuno-oncology and neurodegenerative diseases benefit from PerkinElmer's extensive reagents portfolio

Plus, you don't want to miss our quiz for a chance to win a fun event for your lab! We look forward to seeing you there!

Natasa, Taylor and Serena
Your Drug Discovery Reagent Team

On Monday, February 14th from 12pm-2pm we will be on-site to mix, mingle, and share details on how we can help you save money.

Meet your Account Manager, Brittany Gigliotti-Betts along with Immunoassay Specialist Daniel Kim to learn all about:

• Our awesome New Lab Start Up Program
• What makes our ELISA kits so special
• How our custom pre-mix MILLIPLEX kits work

Moving soon? We will also have a Lab Water Specialist with us to chat through any questions you may have about getting your new space ready to go! Please select a time-slot Add-On when registering to ensure one-on-one time is set aside.

We will be providing snacks and refreshments, so set some time aside to put your feet up and enjoy a moment with the MBC BioLabs community.

AbbVie and MBC BioLabs invite entrepreneurial scientists and founders to apply for a 2022 AbbVie Golden Ticket. The AbbVie Golden Ticket provides a year's use of a lab bench and core facilities at MBC BioLabs' San Francisco or San Carlos site, as well as opportunities to engage with AbbVie scientific and business leaders. It will be awarded to two early-stage companies developing novel, transformational therapies for autoimmune, oncology, neuroscience, eye care or aesthetics.

The ideal candidate for winning an AbbVie Golden Ticket will meet the following criteria:

• Focused on science / technology with potential to generate transformational therapies in areas that align strategically with AbbVie's therapeutic areas of interest (listed above and additional details available here)
• Developing therapeutic platform technologies, including gene therapy, novel cell therapy, gene editing, or novel drug-discovery or platform technologies
• Exclusions: Diagnostics, Devices, Research Tools, and Healthcare Services/IT

A IsoLight is now available @ MBC BioLabs 733 Industrial facility. The IsoLight is a versatile, precision engineering platform designed to understand and characterize differences among single cells, map thousands of cells per sample, and reveal full functional profiles and polyfunctionality among cell subsets to determine patient response and product quality.

Arda Therapeutics is a seed-stage biotech taking aim at chronic diseases and aging by eliminating the pathological cells that drive these conditions. Arda's platform starts from single-cell patient data to identify which cells to target and how to target them. They then design immunotherapies to clear those cells, and only those cells.

Dynomics is delivering targeted therapies to restore heart function, and eliminate heart failure. We built HeartDyno, our cardiac discovery engine, to overcome the historical low productivity in cardiac drug development. HeartDyno is built on functional human heart tissues, painstakingly engineered by our team over a decade to be both authentic and high-throughput. This finally allows for functional safety and efficacy to be built in at earliest stages of drug discovery, and uniquely powers our team to change the game in cardiovascular disease.